Metrifonate (trichlorfon): A review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 8, Issue 4, 1999, Pages 463-471

  Ringman, J M ^a   Cummings, J L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholinesterase inhibition; Alzheimer's disease; Behavioural cognition; DDVP; Dementia; Dichlorvos; Metrifonate; Trichlorfon

Indexed keywords

ACETYLCHOLINESTERASE; ANTHELMINTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; METRIFONATE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; APLASTIC ANEMIA; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; REVIEW; SCHISTOSOMIASIS; SWEATING; VOMITING;

EID: 0032940239     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.8.4.463     Document Type: Review

References (41)